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Abstract
Background: Fecal microbiota transplantation (FMT) induces remission in ulcerative colitis (UC). However, the
treatment effect of FMT diminishes over time. Maintaining the diversity of the gut flora for long periods may
improve the effects of FMT in UC. Pectin, which can be fermented by gut microbiota into short-chain fatty acids, is
postulated to shape the composition and maintain the balance of gut microbiota following transplantation. This
study investigated whether pectin could enhance the effects of FMT in UC patients.
Results: Three FMT patients and four FMTP patients achieved the primary outcome. The Mayo scores of the FMTP
group were lower than those of the FMT group at weeks 4 and 12 (P = 0.042 and P = 0.042, respectively). There
were no differences in the diversity of the gut flora between the two groups at weeks 4 and 12; however, the
composition of the gut flora of the FMTP group was more similar than the FMT group to that of the donor at all-
time points post-treatment.
Conclusions: Pectin decreased the Mayo score by preserving the diversity of the gut flora following FMT for UC.
Trial registration: Current Controlled Trial NCT02016469. Registered 10 November 2013
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Background
Ulcerative colitis (UC) is a lifelong disease caused by an
interaction between genetic and environmental factors.
The precise etiology is unknown, and therapeutic op-
tions are limited. Fecal microbiota transplantation
(FMT), infusion of a fecal preparation from a healthy
donor into the gastrointestinal (GI) tract of a patient,
has been trialed as a therapeutic approach to diseases
associated with dysbiosis of the gut [1]. FMT is an ef-
fective therapy for recurrent Clostridium difficile infec-
tion [2, 3], but outcomes of FMT in patients with other
GI diseases, such as UC, have been varied [4–7]. Most
studies of UC have suggested that FMT initially pro-
duces beneficial effects, but these are diminished over
time.
Apple-derived pectin is a soluble fiber. It can be
fermented by gut microbiota in the colon into short-
chain fatty acids (SCFA). Pectin may also help main-
tain the balance of gut microbiota [8]. SCFA are be-
lieved to exert numerous effects on the gut, such as
regulating intestinal immunity, and supplying energy
for the colon epithelium. It has been reported that
the SCFA butyrate can induce remission in a mouse
model of UC by reducing the intestinal inflammation
[9]. However, there have been few clinical studies in-
vestigating changes in the intestinal microbiota fol-
lowing FMT in UC patients, or the extent to which
donor bacteria can colonize in the recipient. The aims
of the present study were to determine whether gut
dysbiosis in UC patients could be reversed by FMT,
and whether pectin delays the loss of flora diversity
and improves the effects of FMT.* Correspondence: gongjianfeng@aliyun.com; liningrigs@vip.sina.com
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This study included a single-center, randomized trial of
FMT versus FMT combined with pectin treatment
(FMTP) in patients with active UC admitted to the
Inflammatory Bowel Disease (IBD) Treatment Center of
Jinling Hospital between September 2013 and February
2015. The diagnosis of UC was made according to stand-
ard criteria. All participants provided written informed
consent. The study was approved by the Institutional
Ethics Committee of Jinling Hospital. Inclusion criteria
were as follows: (1) age from 18 to 70 years; (2) Mayo
score of 2–10 at enrollment. Exclusion criteria were as fol-
lows: (1) pregnancy or intention to become pregnant dur-
ing the study period; (2) participation in any other clinical
trials within the previous 3 months; (3) infectious colitis
[6, 10]; (4) use of anti-TNF or methotrexate treatment
within 8 weeks of inclusion; (5) use of antibiotics or pro-
biotics within 4 weeks of inclusion. Subjects were allowed
with stable doses of mesalamine or corticosteroids before
inclusion [6].
Program
Twenty patients were randomly divided into the two
treatment groups (FMT and FMTP). All patients under-
went FMT via colonoscopy, and the FMTP group also
took oral doses of pectin (20 g/d, 50 % wt/wt) for five
consecutive days following FMT. Mayo score, C-reactive
protein (CRP) level, erythrocyte sedimentation rate
(ESR), and Inflammatory Bowel Disease Questionnaire
(IBDQ) criteria were recorded at enrollment and at
weeks 4 and 12 post-treatment. Fecal samples were col-
lected upon enrollment and at weeks 4 and 12 for bac-
terial spectrum analysis and fecal calprotectin analysis.
Donor
The standardized stool donor was a healthy, unrelated
adult (22-year-old female) who had not received anti-
biotic therapy in the 4 weeks prior to donation. The
donor had no history of intestinal disease or recent
gastrointestinal infection, autoimmune or other immune-
mediated diseases, or malignancies. Chronic hepatitis B
and C, human immunodeficiency virus, and syphilis were
excluded serologically, and the donor’s stool was negative
for C. difficile, enterohemorrhagic Escherichia coli,
Salmonella, Shigella, Yersinia, Campylobacter, and
parasites. Donor stool samples were randomly col-
lected, and the bacterial spectrum was confirmed to
be stable using 16S rRNA high-throughput analysis
(Additional file 1: Figure S1).
Donor material preparation
Aliquots (60 g) of fresh (within 6 h of defecation) fecal
sample were blended with 500 ml of sterile saline for
10 min, and then filtered through three gauze pieces to
remove larger sediment. The filtered fecal preparation
was stored at 4 °C until FMT was performed.
Transplantation procedure
Patients were maintained on vancomycin (500 mg orally,
twice daily for three consecutive days) until 12 h prior to
the FMT procedure. Polyethylene glycol electrolyte pow-
der was used for intestinal preparation [3]. Donor mater-
ial (300 ml) was administered via colonoscopy biopsy
channel.
Analysis of microbial diversity
Microbial DNA was extracted from fecal samples using
an E.Z.N.A. DNA Kit (Omega Bio-tek, Norcross, GA,
USA) according to the manufacturer’s protocols. The
V4–V5 regions of the bacterial 16S ribosomal RNA gene
were amplified by PCR (95 °C for 2 min, followed by
25 cycles of 95 °C for 30 s, 55 °C for 30 s, and 72 °C for
30 s, and a final extension of 72 °C for 5 min) using
primers 515F (5′-barcode-GTGCCAGCMGCCGCGG-
3′) and 907R (5′-CCGTCAATTCMTTTRAGTTT-3′),
where the barcode was an eight-base sequence unique to
each sample. Reactions were performed in triplicate in a
20-μl volume containing 4 μl of 5× FastPfu Buffer, 2 μl
of 2.5 mM dNTPs, 0.8 μl of each primer (5 μM), 0.4 μl
of FastPfu Polymerase, and 10 ng of template DNA.
Amplicons were extracted from 2 % agarose gels and
purified using an AxyPrep DNA Gel Extraction Kit
(Axygen Biosciences, Union City, CA, USA) according
to the manufacturer’s instructions, and quantified using
QuantiFluor-ST (Promega, Madison, WI, USA). Purified
amplicons were pooled in equimolar concentrations, and
paired-end sequenced (2 × 250) on an Illumina MiSeq
platform (Illumina, San Diego, CA, USA) according to
standard protocols. The raw reads were deposited in the
NCBI Sequence Read Archive (SRA) database.
Fecal calprotectin (FC) test
Extract was added to 50–100 mg of stool sample until
the weight:volume (g/ml) ratio reached 1:49. Following
vigorous shaking, a 2-ml aliquot of this mixture was cen-
trifuged for 5 min at 10,000 × g. The supernatant was
used for detection of FC in accordance with the kit in-
structions (Buhlmann Company, Switzerland). Absorb-
ance was measured at 450 nm. Normal levels of fecal
calprotectin are <30 μg/g.
Definition of clinical outcome
Patients were monitored for 12 weeks after treatment.
Mayo scores ≤ 2 at week 12 were considered indicative
of clinical remission [11–13]. A reduction in the total
Mayo score of > 30 % from baseline, a 1-point improve-
ment in tarry stools, or an increase of > 16 points in
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IBDQ criteria at week 12 were considered clinical re-
sponses. Two gastroenterologists specializing in IBD
assessed the Mayo scores. Adverse events were docu-
mented for up to 12 weeks.
Statistical analysis
R statistical software (version 3.1.1; http://cran.r-
project.org) was used for all statistical analyses un-
less specified. All data are expressed as means ± SEM.
Comparison within groups was performed using a
Student’s t-test. An operational taxonomic unit (OTU)
was defined using a threshold of 97 % identity by Usearch
(version 7.1; http://drive5.com/uparse). A ribosomal data-
base project classifier was used for taxonomic assignment
of all sequences at the 70 % confidence level [14]. The
most abundant sequence of each OTU (97 % similarity)
was searched against the Silva database [15] (Release 119;
http://www.arb-silva.de) using BLAST analysis to deter-
mine the phylogeny of the OTUs. Diversity was estimated
using the Shannon diversity index (H’) (R package 2.7.1).
Relative abundances of the OTUs at the phylum, class,
order, family, genus, and species levels were calculated for
each sample and used for principal component analysis
(PCA), correlation analysis, and comparison analysis. The
Pearson correlation coefficient (r) and Student’s t-test
were used for correlation and comparison analysis, re-
spectively. Significance was set at P < 0.05.
Results
Baseline characteristics of patients
Basic information on the 20 enrolled patients is shown
in Table 1. All patients completed their treatment proto-
col, and stool samples were collected for microbiome
analysis and FC test. Five stool samples were missed in
the FMT group, and three in the FMTP group.
Changes in clinical outcome
There were no significant differences in CRP level, ESR,
IBDQ criteria, or FC level between the two groups at
weeks 4 or 12 (Fig. 1a–d). However, Mayo scores were
significantly lower in the FMTP group than in the FMT
group at both time points (4 weeks: 1.25 ± 0.38 vs.
3.60 ± 1.52, P = 0.042; 12 weeks: 2.25 ± 0.75 vs. 4.20 ± 0.96,
P = 0.042). In addition, for both groups, the Mayo score
was higher at week 12 than at week 4, indicating that the
effect of FMT gradually decreased over time (Fig. 1e). At
week 12, 30 % (3/10) of patients in the FMT group and
40 % (4/10) in the FMTP group achieved remission, while
70 % (7/10) and 60 % (6/10), respectively, had a clinical re-
sponse. In the FMT group, three patients had a reduction
in total Mayo score of > 30 %, two had a 1-point improve-
ment in tarry stools, and four patients had increases in
IBDQ criteria of > 16 points. In the FMTP group, four pa-
tients showed a reduction in Mayo score of > 30 %, four
had a 1-point improvement in tarry stools, and six pa-
tients had increases in IBDQ criteria of > 16 points.
Changes in the gut microbiota
Eighteen samples in the FMTP group and 15 in the
FMT group were analyzed using 16S rRNA-based profil-
ing. Both treatments resulted in an increase in the
Shannon diversity index compared with the baseline, in-
dicative of greater species diversity. There was no obvi-
ous difference in fecal flora diversity (Shannon index)
between the two treatment groups at weeks 4 or 12
post-transplantation (Fig. 1f, Fig. 2). To allow compari-
son, the Shannon index was set to 1.41 as a reference
value. This was the minimum value of the diversity of
the donor, and it was used to indicate how many sam-
ples had larger indexes than the reference value in either
of the groups. At week 4, 77.8 % (7/9) of samples in the
FMTP group and 75.0 % (6/8) in the FMT group had
Shannon indexes > 1.41. At week 12, 77.8 % (7/9) of
samples in the FMTP group but only 42.9 % (3/7) in the
FMT group had Shannon indexes > 1.41 (Table 2), indi-
cating that pectin helped to delay the loss of diversity in
the fecal microbiota. This may be related to the lower
Mayo scores observed in the FMTP group at weeks 4
and 12.
Changes in the abundance of lower taxonomic ranks,
such as increased numbers of Enterobacteriaceae, have
been reported in patients with UC. In the current study,
Shiga toxin-producing E. coli accounted for 16.8 % of
the total gut bacterial population in UC patients prior to
FMT, then decreased to 1.28 % at week 4, and returned
to 13.8 % at week 12. The abundance of Shiga toxin-
producing E. coli in the FMTP group at week 12 was
only 0.88 % (Table 3).
PCA based on the relative abundance of OTUs in four
assigned groups (donor, before treatment, FMT, and
Table 1 Basic patient information (data are expressed as
mean ± SEM)





Prednisone 0 2(combined with 5-ASA)
Mesalazine suppository 3 1
Course of disease(years) 4.5(3) 4(2)




Mayo score 6.60(1.12) 4.75(0.75)
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FMTP) revealed a separation between groups on the
basis of the first two principal component (PC) scores.
The distances of samples in the donor group were much
shorter, while samples in other groups were dispersed.
To measure the distances between the samples, a circle
of influence was defined for each group. The x- and y-
value of the center of the circle of influence were defined
as the average PC1 and PC2 values of each sample in
the group. The radius was the average distance between
the center and each sample in the group. There were
three samples in the FMTP group within the circle of in-
fluence of the donor, and the left-most samples in the
group were also closer to the circle, indicating that the
composition of the microbiota of the FMTP samples was
more similar to the donor than the FMT group (Fig. 3).
To further assess the efficiency of the two treatment
protocols, we calculated the Person correlation coeffi-
cient (r) between the samples and the donor to compare
the coefficients of post-treatment samples and pre-
treatment samples. In the FMTP group, 55.6 % of the
samples had larger correlation coefficients with the
donor after treatment than untreated samples. In the
FMT group, the percentage was 46.7 % (Fig. 4).
The composition of the microbiota in the FMT and
FMTP groups was also compared at the phylum, class,
order, family, genus, and species levels (Table 4). The
differences in composition between the donor, FMTP,
and FMT groups are shown in Additional file 1.
Adverse events
The overall incidence of adverse events was 15 % (3/20).
One patient showed intolerance to FMT and immediate
leakage of donor material within 30 min of the procedure.
Two patients developed fevers following FMT. None of
the other patients experienced serious adverse events.
Discussion
UC is a chronic inflammatory condition of the colon. It
is caused by an inappropriate immune response to lu-
minal antigens. In genetically susceptible hosts, specific
changes in the composition of the intestinal microbiota
can lead to activation of the mucosal immune system,
resulting in chronic inflammation of the colonic mucosa
[16]. Evidence from several studies has highlighted alter-
ations in abundance and diversity of the intestinal
microbiota in patients with UC.
Theoretically, introduction of probiotics may alter the
dysbiosis and the aberrant immune response in UC,
resulting in clinical improvement of the disease. Gut
microbiota have emerged as a potential therapeutic tar-
get and a repository for novel drug discovery. Commer-
cially available probiotics used in treatment of UC
mostly include Lactobacillus and Bifidobacterium spe-
cies, with the anaerobes that comprise most of the intes-
tinal flora having been subjected to less exploration [5].
FMT, which contains the whole microbiome, was devel-
oped as a treatment to restore the commensal bacteria
of patients suffering from disease-related dysbiosis.
The application of FMT for UC has been described in
several publications. Previous meta-analysis showed that
63 % of patients with UC underwent remission following
FMT, 76 % were able to stop taking medications, and
76 % experienced improvement in gastrointestinal symp-
toms [4]. However, several randomized controlled trials
in 2015 showed conflicting results of FMT in UC cases
[5–7]. Maintaining the diversity of flora over a long
Fig. 1 Changes in clinical indicators over time for the FMT and FMTP groups. a-d Erythrocyte sedimentation rate, C-reactive protein levels,
Inflammatory Bowel Disease Questionnaire score, and fecal calprotectin levels for the two groups prior to treatment and at weeks 4 and 12 post-
treatment. e Mayo scores at weeks 4 and week 12 post-treatment. f Comparison of community diversity in the two groups
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period would improve the clinical outcome and delay
the recurrence of disease following FMT for treatment
of UC.
SCFA, especially butyrate, have significant effects on
the intestine [9, 17, 18]. Soluble dietary fiber may serve
as a precursor of SCFA. No previous study has ad-
dressed whether SCFA can improve the effects of FMT
in UC cases. Pectin, a polysaccharide that can be fermen-
ted into SCFA by commensal bacteria, is widely used in
medicine and the food industry. The results of the current
study show that pectin enhances the efficacy of FMT, as
indicated by lower Mayo scores at 4 and 12 weeks in the
FMTP group. Further analysis showed that pectin did not
increase the diversity of the fecal microflora, but can delay
the deterioration of bacterial diversity.
Differences in the short-term effects of FMT in the
current study compared with those observed in previous
Fig. 2 Fecal flora composition of the FMT and FMTP groups after transplantation. a and b Fecal flora composition at the genus level for the two
groups 4 weeks post-transplantation. c and d Fecal flora composition at the genus level of the two groups 12 weeks post-transplantation
Table 2 Percentages of patients with a Shannon index > 1.41
Indicators FMTP FMT
Week 4 Week 12 Week 4 Week 12
Number of samples 9 9 8 7
Number of samples with Shannon
index larger than 1.41
7 7 6 3
Percentage of samples with
Shannon index larger than 1.41 (%)
77.78 77.78 75 42.86
Table 3 Percentages of Shiga toxin-producing Escherichia coli in
different groups during the experimental period
Before 4 weeks after FMT 12 weeks after FMT
FMT 16.84 % 1.77 % 26.69 %
FMTP 15.77 % 0.78 % 0.88 %
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studies might be explained by the following factors
[19, 20]. Only a single infusion was administered in
the current study, as it is impractical to perform repeated
colonoscopies over consecutive days. In addition, many
protocols recommend bowel preparation and antibiotics
prior to FMT to assist in the colonization of microbiota
[21]. While these steps were performed in the current
study, the impact of colonic lavage and antibiotic therapy
on ulcerative colitis activity is unknown [22].
Several changes in the composition of the intestinal
microbiota at the phylum level have been linked to
UC. These include a reduction of Firmicutes and
Bacteroidetes, and an increase in Proteobacteria and
Actinobacteria. In this study, the levels of Bacteroidetes
increased following treatment in both the FMTand FMTP
groups, but no significant changes were observed in the
abundance of Firmicutes, Proteobacteria, and Actinobac-
teria during the study period. The composition of the
Fig. 3 More samples closer to the donor in group FMTP than in group FMT after treatment in the PCA picture showing FMTP is more effective in
maintaining the diversity of the flora
Fig. 4 Pearson correlation coefficient (r) between OTU values of each sample and the donor were calculated and compared to make out whether
post-treatment r of the sample and donor were greater than pre-treatment. 55.56 % of the post-treatment samples had larger r with the donor than
untreated samples in FMTP group (a) but only 46.67 % in FMT group (b)
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intestinal microbiota was also compared at six taxonomic
levels. There were no significantly different OTUs at the
phylum or order levels. At class level, Betaproteobacteria
were less abundant in the FMTP group. At the family
level, Acidaminococcaceae and Alcaligenaceae were more
abundant, while Lactobacillaceae were less abundant in
the FMTP group. At the genus level, two genera, Rumino-
coccus and Turicibacter, were more plentiful in the FMTP
group, but the abundance of Sutterella species was de-
creased. Pectin fermentation is relatively common among
Bacteroides species, but among Gram-positive anaerobes,
including Firmicutes and actinobacterial species, it is only
performed by Eubacterium eligens. Dongowski et al. found
that Bacteroides thetaiotaomicron, a Gram-negative anaer-
obe that is common in the gut, was accompanied by in-
creased formation of SCFA from pectin. In the current
study, changes in the bacterial composition were only ana-
lyzed during the bioinformatics analysis step. As such, the
specific bacterial species composition associated with pec-
tin degradation was not determined. However, this is
something we will continue to explore, and we hope to
focus future studies on identifying which bacterial genera
are involved in pectin degradation and improvement of
Mayo scores in UC patients.
Table 4 Differences in the composition of gut microflora following FMT or FMTP
Level Differences P-value Up or downa
Phylum – – –
Class Betaproteobacteria 0.0031 down
Order – – –
Family Acidaminococcaceae 0.0167 up
Alcaligenaceae 0.0104 up
Lactobacillaceae 0.0438 down
Genus Ruminococcus 0.0257 up
Sutterella 0.0238 down
Turicibacter 0.0232 up
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Class Betaproteobacteria 0.0031 down
Order – – –
Family Acidaminococcaceae 0.0167 up
Alcaligenaceae 0.0104 up
Lactobacillaceae 0.0438 down
Genus Ruminococcus 0.0257 up
Sutterella 0.0238 down
Turicibacter 0.0232 up







aRelative to the FMT group
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As FMT as a therapeutic approach has evolved, ethical
issues around the public aesthetic and access to medical
technology have become a focal point. The fact that the
treatment involves the transfer of fecal matter greatly re-
duces its acceptance; however, research indicates that
most UC patients would accept FMT to alleviate symp-
toms and improve quality of life. As such, aesthetic re-
quirements are not a high priority. Researchers are
constantly trying to improve FMT, including the devel-
opment of FMT capsules, which would further reduce
the visual and olfactory impediments. Another problem
is medical technology standardization issues. A consen-
sus needs to be reached regarding bowel preparation
prior to FMT, selection criteria for the donor and recipi-
ent, and the route of transplantation. Therefore, further
multi-center randomized controlled trials and cooper-
ation between research groups are needed to develop a
standard and effective FMT procedure. This study has
several limitations, including the small number of sub-
jects and that patients with severe UC were excluded.
Drug therapy before and after FMT may also influence
the results. Further trials enrolling a larger number of
patients, and allowing patients to stop medication to ob-
serve the effect of FMT on UC, are needed. However,
the current study confirmed that pectin delayed the loss
of diversity of transplanted gut flora, and enhanced the
effects of FMT in UC cases.
Conclusion
FMT has a short-time effect for mild to moderate UC
and pectin further decreased the Mayo score by preserv-
ing the diversity of the gut flora following FMT for UC
and enhanced the effect of FMT.
Additional file
Additional file 1: Figure S1. Community structure of random donor
stool samples. (TIF 103 kb)
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